Long-term follow-up of a child treated with efalizumab for atopic dermatitis [4]

Archives of Dermatology

Volumn 143, Issue 8, 2007, Pages 1077-1078

  Siegfried, Elaine C ^a  

^a Kids Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; GAMMA INTERFERON; IMMUNOGLOBULIN; TACROLIMUS;

ATOPIC DERMATITIS; AUTOIMMUNE THROMBOCYTOPENIA; CASE REPORT; DRUG WITHDRAWAL; ECZEMA; FOLLOW UP; HAIR GROWTH; HUMAN; IMMUNOMODULATION; LETTER; LONG TERM CARE; MALE; MONOTHERAPY; PETECHIA; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ANTIBODIES, MONOCLONAL; CHILD; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MALE; THROMBOCYTOPENIA;

EID: 34548099837     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.8.1077     Document Type: Letter

References (2)

1. Rapaport M. Rebound vasodilation from long-term topical corticosteroid use. Arch Dermatol. 2007;143(2):268-269.
2. Takiguchi R, Tofte S, Simpson B, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol. 2007;56(2):222-227.